426
Participants
Start Date
December 31, 2009
Primary Completion Date
September 30, 2010
Study Completion Date
September 30, 2010
TAK-875
TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
TAK-875
TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
TAK-875
TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
TAK-875
TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
TAK-875
TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
Glimepiride
TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
Placebo
TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
Birmingham
Hoover
Tucson
Anaheim
Burlingame
Chula Vista
Fresno
Los Angeles
Los Gatos
Norwalk
Orange
Colorado Springs
Pueblo
Boca Raton
Clearwater
Hialeah
Jupiter
Miami
New Port Richey
Ocala
Panama City
Pembroke Pines
Tampa
Sandy Springs
Honolulu
Chicago
La Grange
Sunset
Portland
Parkville
Rockville
Southfield
Olive Branch
St Louis
Las Vegas
Berlin
Camden
West Seneca
Asheboro
Burlington
Charlotte
Morehead City
Statesville
Winston-Salem
Carlisle
Cleveland
Columbus
Perrysburg
Norman
Oklahoma City
Altoona
Tipton
Cranston
Peak
Taylors
Varnville
Corpus Christi
Hurst
North Richland Hills
Odessa
San Antonio
Draper
Salt Lake City
Spokane
Guatemala City
Guadalajara
Zapopan
Mexico City
Cuernavaca
Monterrey
Tampico
Lead Sponsor
Takeda
INDUSTRY